Skip to content

Effects of vitamin D supplement with RAI treatment in patients with Graves disease:results of a randomized clinical trail

Effects of vitamin D supplement with RAI treatment in patients with Graves disease:results of a randomized clinical trail

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096674
Enrollment
Unknown
Registered
2025-01-31
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves disease

Interventions

131I treatment+ vitamin supplement
131I treatment:vitamin supplement
131I treatment:no intrvention

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with Graves' disease who were eligible for 131I treatment, were over 18 years of age, did not receive vitamin D supplementation before treatment, and were willing to take oral vitamin D regularly. The diagnostic criteria for Graves' disease were: (1) Hyperthyroidism (abbreviated as hyperthyroidism) was established; (2) Diffuse enlargement of thyroid gland; (3) exophthalmos and other infiltrating eye signs; (4) anterior tibial mucous edema; (5) TRAb and thyroid peroxidase antibody (TPOAb) were positive. Among them, (1) (2) are the necessary conditions for diagnosis, (3) (4) and (4) are the auxiliary conditions for diagnosis.

Exclusion criteria

Exclusion criteria: Pregnant and lactating patients; Patients who have taken vitamin D supplementation, patients with III degree thyroid enlargement; Patients with persistent hypercalcemia (blood calcium greater than 2.8mmol/L); Patients with renal insufficiency (eGFR<45 mL/min); Patients with malignant tumor; Patients taking immune-modulating drugs; Patients with alcohol or drug abuse; Patients allergic to vitamin D preparations;

Design outcomes

Primary

MeasureTime frame
TSH;FT4;TRAb;

Secondary

MeasureTime frame
25-OH-VD;

Countries

China

Contacts

Public ContactLin Li

West China Hospital of Sichuan University

lilinhuaxi@sin.com+86 189 8060 1584

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026